Director Katherine Baicker filed a Form 4 with the SEC on November 17, 2026, disclosing an acquisition of Eli Lilly common stock on November 16, 2026.

Key Highlights

  • Reporting person: Katherine Baicker, identified as a Director of Eli Lilly & Co (NYSE:LLY).
  • Shares acquired: 167.6364 shares of Common Stock acquired on November 16, 2026, with transaction code "A" (acquired).
  • Price per share: $1,431.67, as stated in the filing.
  • Post-transaction holdings: Baicker directly beneficially owned 23,815.4982 shares of Common Stock following the transaction.
  • Filing signed: Jonathan Groff signed on behalf of Katherine Baicker pursuant to authorization on file, dated November 17, 2026.

Baicker's November 2026 Common Stock Acquisition at Eli Lilly

According to the Form 4 filed with the SEC, Katherine Baicker, a Director at Eli Lilly & Co (NYSE:LLY), acquired 167.6364 shares of the company's Common Stock on November 16, 2026. The filing records the transaction under code "A," indicating the shares were acquired. The price listed in the filing is $1,431.67 per share.

Following this transaction, the filing reports that Baicker directly beneficially owned 23,815.4982 shares of Eli Lilly Common Stock. No derivative securities were reported in Table II of the filing. The form was filed on November 17, 2026, one day after the transaction date, and was signed by Jonathan Groff on behalf of Katherine Baicker pursuant to an authorization on file.

The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires directors, officers, and certain shareholders to report changes in their beneficial ownership of company securities. No amendment date was indicated, suggesting this is an original filing.

What Was Disclosed

The filing disclosed a single acquisition of 167.6364 shares of Eli Lilly Common Stock by Director Katherine Baicker on November 16, 2026, at $1,431.67 per share, bringing her direct beneficial ownership to 23,815.4982 shares.